Send to

Choose Destination
J Cell Mol Med. 2018 Jul;22(7):3464-3474. doi: 10.1111/jcmm.13624. Epub 2018 Apr 27.

Development of GMP-1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer's disease.

Author information

Division of Neurogeriatrics, Department of Neuroscience Care and Society, Karolinska Institutet, Huddinge, Sweden.
GreatMatterPharma AB, Solna, Sweden.
QPS Austria GmbH, Grambach, Austria.
NeuroScios GmbH, Radegund/Graz, Austria.


Mitochondrial dysfunction is an early feature of Alzheimer's disease (AD) and may play an important role in the pathogenesis of disease. It has been shown that amyloid beta peptide (Aβ) and amyloid precursor protein (APP) interact with mitochondria contributing to the mitochondrial dysfunction in AD. Prevention of abnormal protein targeting to mitochondria can protect normal mitochondrial function, increase neuronal survival and at the end, ameliorate symptoms of AD and other neurodegenerative disorders. First steps of mitochondrial protein import are coordinated by molecular chaperones Hsp70 and Hsp90 that bind to the newly synthesized mitochondria-destined proteins and deliver them to the protein import receptors on the surface of organelle. Here, we have described the development of a novel compound named GMP-1 that disrupts interactions between Hsp70/Hsp90 molecular chaperones and protein import receptor Tom70. GMP-1 treatment of SH-SY5Y cells results in decrease in mitochondria-associated APP and protects SH-SY5Y cells from toxic effect of Aβ1-42 exposure. Experiments in drosophila and mice models of AD demonstrated neuroprotective effect of GMP-1 treatment, improvement in memory and behaviour tests as well as restoration of mitochondrial function.


Alzheimer's disease; dicarboxylate clamp; mitochondria; molecular chaperones; protein import; tetratricopeptide repeat proteins

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center